Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

GlobenewswireRead the rest

Elusive or Not, Aβ Oligomers Are in BioPharma Crosshairs

ALZ ForumRead the rest

Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

Alzheimer’s News TodayRead the rest

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

GlobenewswireRead the rest

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

EconoTimesRead the rest

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

GlobenewswireRead the rest

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

Globe NewswireRead the rest

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Globe NewswireRead the rest

FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track

Alzheimer’s TodayRead the rest

First-in-Class Alzheimer’s Drug Gets Fast-Tracked by FDA

MPRRead the rest

Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812

Clinical LeaderRead the rest

Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

GlobenewswireRead the rest

Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day

Globe NewswireRead the rest

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

Globe NewswireRead the rest

Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors

Globe NewswireRead the rest

Lazard exec joins Cognition Therapeutics board

Pittsburgh Business TimesRead the rest

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Globe NewswireRead the rest

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

Globe NewswireRead the rest

Cognition Therapeutics $6.50 million Financing

FairHeraldRead the rest

Cognition Therapeutics aims to stop memory loss with breakthrough Alzheimer’s drug

click hereRead the rest

Cognition Therapeutics initiates U.S. testing for Alzheimer’s Drug

click hereRead the rest

Cognition Therapeutics Initiates US Clinical Testing Of CT1812, A Novel Small Molecule For The Potential Treatment Of Alzheimer’s Disease

click hereRead the rest

Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease

click hereRead the rest

Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

click hereRead the rest

CogRX: Society for Neuroscience 2016 Annual Meeting Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics”

click hereRead the rest

Form D To Observe: Cognition Therapeutics $3.00 million Financing. Kenneth I Moch Submitted Nov 30 Filing

click hereRead the rest

CogRX: 1st Alzheimer’s Patient Dosed in Clinical Trial of Amyloid Beta ‘Displacer’

click hereRead the rest

CogRx sees Lilly solanezumab results support for its unique mechanism for Alzheimer’s disease treatment

click hereRead the rest

Cognition Therapeutics Sees Lilly Solanezumab Clinical Trial Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease

click hereRead the rest

Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812

click hereRead the rest

Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO

click hereRead the rest

Cognition Therapeutics: Cognitive impairment pipeline market analysis H2 2016 examined in new market research report

click hereRead the rest

Cognition Therapeutics launching clinical trials for Alzheimer’s drug in Australia

click hereRead the rest

Cognition Therapeutics: Five things to know today

click hereRead the rest

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease

click hereRead the rest

Drug development is on the rise in Pittsburgh, but there’s room to grow

click hereRead the rest

Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association

Named after Tech Coast Angels’ inspiring co-founder, the annual award goes to most outstanding and innovative early stage  company

May 18, 2016 – IRVINE, Calif. – Tech Coast Angels (TCA) today announced that the Angel Capital Association (ACA) had awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia.… Read the rest

Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association

Click hereRead the rest

Angels hail Pittsburgh company Cognition Therapeutics as most innovative startup

click hereRead the rest

Pittsburgh Life Sciences Greenhouse Portfolio Company Cognition Therapeutics Wins Angel Capital Association’s Luis Villabos Award

click hereRead the rest

Tech Coast Angels Invested Best Ever $16.37 Million in 2014

Southern California Angel Network Surpasses Previous Records for Both Investments and Activity

IRVINE, Calif. January 29, 2015 Tech Coast Angels (TCA) invested a total of $16,373,337 in 61 total deals in Calendar Year 2014. The angel network announced that 2014 was the most active year since the networks inception in 1997 for number of deals funded, and capital raised was also the largest ever.… Read the rest

Tech Coast Angels Invests More Than $4.5 Million in 1H 2012

Largest Angel Network in United States Invests in 17 Innovative Companies Across Broad Range of Industries

IRVINE, Calif. – August 15, 2012 – Tech Coast Angels (TCA) raised more than $10 million of total investment in 17 innovative companies, including $4,571,000 of direct TCA investment, during the first half of 2012 via the group’s five networks (Los Angeles, Orange County, San Diego, Central Coast, and Inland Empire).… Read the rest

TECH COAST ANGELS FUNDS 31 DEALS IN 2010 AND HIGHLIGHTS THREE PROFITABLE EXITS

IRVINE, Calif., February 22, 2011 Tech Coast Angels (TCA), the nations largest angel investment network, today announced it funded 31 investments, including 12 new deals and 19 follow-on investments in a broad range of start-up businesses, demonstrating its angel investment leadership.… Read the rest

TCA portfolio company Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer’s Disease Drug Treatment Program

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ — Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status.… Read the rest

Tech Coast Angels Companies Receive More Than $1B

30 TCA Portfolio Companies Secure More Than 75M in 2008

LOS ANGELES – February 23, 2009 – Tech Coast Angels (TCA), the largest angel network in the United States, today announced that more than $1B has been invested in TCA-funded companies since the group’s inception in 1997.
Read the rest